Clolar Related Published Studies
Well-designed clinical trials related to Clolar (Clofarabine)
Clofarabine +/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. [2011.06]
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. [2008.09.01]
Other research related to Clolar (Clofarabine)
Clofarabine doubles the response rate in older patients with acute myeloid
leukemia but does not improve survival. [2013]
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. [2011.08.20]
Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. [2011.08]
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. [2011.07.12]
Clofarabine (2-chloro-2'-fluoro-2'-deoxyarabinosyladenine)--biochemical aspects of anticancer activity. [2011.07]
A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma. [2011.07]
Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation. [2011.05]
Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. [2011.04.01]
Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. [2011.04]
Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. [2011.04]
Nursing considerations for optimal outpatient management of adult patients with leukemia treated with clofarabine. [2011.02]
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. [2011.01.15]
Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. [2011]
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. [2010.12]
A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine. [2010.12]
Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. [2010.12]
Clofarabine in the treatment of poor risk acute myeloid leukaemia. [2010.09]
Effect of hemodialysis on the plasma levels of clofarabine. [2010.07.15]
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. [2010.06.01]
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. [2010.05.10]
Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. [2010.05]
Fatal neurotoxicity in a patient with down syndrome treated with chemotherapy, irradiation, stem cell transplant, and clofarabine. [2010.04]
Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia. [2010.03]
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. [2010.02.01]
Clofarabine in leukemia. [2010.02]
Mechanisms of anti-cancer action and pharmacology of clofarabine. [2009.12.01]
A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. [2009.12]
Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. [2009.11]
Clofarabine for the treatment of adult acute myeloid leukemia. [2009.10]
Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine. [2009.10]
Clofarabine: emerging role in leukemias. [2009.10]
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. [2009.09.10]
Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. [2009.07]
Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine. [2009.07]
Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity. [2009.06]
Clofarabine: a new treatment option for patients with acute myeloid leukemia. [2009.06]
Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study. [2009.05]
The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. [2009.04]
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. [2009.03]
Clofarabine in refractory Langerhans cell histiocytosis. [2008.11]
Clofarabine combinations as acute myeloid leukemia salvage therapy. [2008.10.15]
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as frontline therapy for patients age >= 60 years with acute myeloid leukemia and high-risk myelodysplastic syndrome. [2008.06.18]
The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report. [2008]
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine. [2007.12]
Clofarabine: past, present, and future. [2007.10]
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. [2007.09.15]
Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia. [2007.09]
A phase I clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. [2007.06.11]
Clofarabine for the treatment of acute lymphoblastic leukemia. [2007.02]
Nursing considerations for clofarabine in the treatment of acute lymphoblastic leukemia in children. [2006.12]
Discovery and development of clofarabine: a nucleoside analogue for treating cancer. [2006.10]
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. [2006.07.01]
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. [2006.04.20]
Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. [2005.12]
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. [2005.05.15]
Clofarabine. [2005.05]
Biochemical modulation of cytarabine triphosphate by clofarabine. [2005.04]
Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia. [2005.03]
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. [2005.02.01]
Clofarabine: in pediatric patients with acute lymphoblastic leukemia. [2005]
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. [2004.11]
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. [2004.10]
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. [2004.02.01]
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. [2003.12.15]
Induction of complete remission using single agent clofarabine in a patient with primary refractory acute myeloblaste leukemia. [2003.12]
Clofarabine. Bioenvision/ILEX. [2003.12]
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. [2003.10.01]
Clofarabine-induced acral erythema during the treatment of patients with myelodysplasia and acute leukemia: report of two cases. [2003.08]
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. [2003.03.15]
Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. [2003.03]
Other possibly related research studies
New nucleoside analogs in the treatment of solid tumors. [2004.07]
New nucleoside analogs in the treatment of hematological disorders. [2004.05]
New designs for phase 2 clinical trials. [2003.07.15]
Hematologic malignancies: new developments and future treatments. [2002.08]
New drugs in acute myeloid leukemia. [2002.09]
Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. [2000.11.15]
Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. [1999]
Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats. [1994]
Gateways to clinical trials. [2006.11]
Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. [2006]
Gateways to clinical trials. [2006.10]
Pharmacological and clinical studies on purine nucleoside analogs--new anticancer agents. [2006.05]
Treatment of older patients with acute myeloid leukemia--new agents. [2006.04]
New agents for the treatment of acute myeloid leukemia. [2006]
Gateways to clinical trials. [2005.09]
New agents in the treatment of childhood leukemias and myelodysplastic syndromes. [2005.11]
Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. [2005.09]
Gateways to clinical trials. [2005.06]
Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. [2004.12]
Gateways to clinical trials. [2004.07]
Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. [2004.08]
Purine nucleoside antimetabolites in development for the treatment of cancer. [2004.06]
Gateways to clinical trials. [2004.01]
Gateways to clinical trials. [2003.12]
Gateways to clinical trials. [2003.11]
Gateways to clinical trials. [2003.07]
Advanced-phase chronic myeloid leukemia. [2003.01]
Nucleoside analogues in the treatment of haematological malignancies. [2001.06]
New directions in the treatment of mantle cell lymphoma: an overview. [2006.10]
|
